BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 8
• 9
• 10
• 11
• 12
• 15
• 16
• 17
• 18
• 19
• 21
• 22
• 23
• 24
• 25
• 26
• 28
• 29
• 30

• Press Releases

  111, Inc. Announces Second Quarter 2025 Unaudited Financial Results

  September 17, 2025

   · 

  20 min read
• Press Releases

  EADV 2025: Almirall Advances Skin Science and Leads Innovation for Holistic Patient Care in Medical Dermatology

  September 17, 2025

   · 

  16 min read
• Press Releases

  ALK and GenSci partner to expand the AIT market in China

  September 17, 2025

   · 

  5 min read
• Press Releases

  Arcutis To Present Multiple New ZORYVE® (roflumilast) Data Analyses at European Academy of Dermatology and Venereology Congress

  September 17, 2025

   · 

  11 min read
• Press Releases

  Celldex Presents Data Demonstrating Barzolvolimab Improves Chronic Spontaneous Urticaria Independent of Baseline Immunoglobulin E levels in Phase 2 Study at EADV Congress 2025

  September 17, 2025

   · 

  8 min read
• Press Releases

  AbTherx and Mosaic Biosciences Forge Exclusive Partnership to Provide Milestone and Royalty-Free Access to AbTherx’s Premier Human Antibody Discovery Technology

  September 17, 2025

   · 

  4 min read
• 

  Obesity

  Lilly Paints ‘Competitive Profile’ for Obesity Pill With Detailed Late-Stage Data

  The over-representation of males and Hispanic patients in Eli Lilly’s Phase III ATTAIN-1 study could explain why orforglipron “underperformed” expectations in a previous readout, according to analysts at BMO Capital Markets.

  September 17, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Manufacturing

  Lilly to Bring Nearly 2,500 Jobs to Virginia With $5B Manufacturing Plant

  This manufacturing site in Richmond, Virginia, is the first of four projects that Eli Lilly plans to reveal this year as part of a $27 billion U.S. investment announced earlier this year.

  September 17, 2025

   · 

  1 min read

   · 

  Tristan Manalac
• 

  Manufacturing

  GSK Commits $30B To Boost US R&D, Manufacturing Operations

  The multi-billion, multi-year investment comes as many of GSK’s pharma peers pull away from the U.K., either suspending or completely canceling previous commitments.

  September 17, 2025

   · 

  1 min read

   · 

  Tristan Manalac
• 

  Layoffs

  Innate Sheds 30% of Staff, Narrows Pipeline Focus Amid ‘Challenging Funding Environment’

  Moving forward, Innate will focus on the clinical development of its antibody-drug conjugate IPH4502, the lymphoma candidate lacutamab and the AstraZeneca-partnered monalizumab.

  September 17, 2025

   · 

  1 min read

   · 

  Tristan Manalac